Which condition is primarily treated by using SABAs?

Short-acting beta-agonists (SABAs) are primarily used in the management of asthma due to their rapid onset of action and effectiveness in relieving acute bronchospasm. They work by stimulating beta-2 adrenergic receptors in the bronchial smooth muscle, leading to relaxation and dilation of the airways, which helps alleviate symptoms such as wheezing, shortness of breath, and coughing.

In asthma, the inflammation and narrowing of airways can lead to episodes of difficulty breathing, and SABAs are effective for quick relief during these acute attacks. They are typically used as a "rescue" medication, providing fast relief from symptoms and improving airflow in the lungs.

While chronic bronchitis, pneumonia, and lung cancer involve significant respiratory issues, they are not primarily treated with SABAs. Chronic bronchitis is often managed with long-acting bronchodilators and anti-inflammatory medications. Pneumonia requires antibiotics and other supportive treatments, while lung cancer management may involve chemotherapy, radiation, or surgical options rather than bronchodilator therapy.